Table 2.

Observed (O) and Expected (E) Numbers of Studies with Statistically Significant (P < 0.05) Results in AlzGene Meta-Analyses with a Statistically Significant Excess Number of “Positive” Studies

Gene	Polymorphism	Odds Ratio	95% Confidence Interval	No. of Studies	O	E	P Valuea	O:E Ratio
ABCA1	rs2066718	1.16	0.74, 1.83	5	2	0.32	0.03	6.25
ACE	Intron 16 (ins/del)	1.07	0.99, 1.16	39	9	2.75	<0.001	3.72
APBB2	hCV1558625	1.12	0.85, 1.46	3	2	0.50	0.08	4.00
APOE promoter	rs769446 (−427)	0.85	0.70, 1.03	12	3	1.08	0.09	2.78
BCHE	rs1803274 K-variant	1.10	0.96, 1.26	27	6	1.80	0.01	3.34
BDNF	C270T	1.11	0.82, 1.51	15	4	0.73	0.01	9.28
BDNF	rs6265 V66M	1.04	0.96, 1.13	20	3	1.06	0.09	2.83
CTSD	rs17571 (A224V)	1.14	0.98, 1.33	22	4	1.58	0.07	2.53
ESR1	PvuII	1.11	0.98, 1.26	15	4	1.45	0.05	2.76
ESR1	XbaI	1.12	0.97, 1.29	16	5	1.58	0.02	3.16
IL6	rs1800795	0.89	0.75, 1.05	14	5	1.85	0.03	2.70
IL10	rs1800871 (−819)	1.04	0.71, 1.53	6	2	0.33	0.04	6.06
IL10	rs1800872 (−592)	1.00	0.78, 1.29	8	2	0.36	0.05	5.56
IL10	rs1800896 (−1082)	0.89	0.72, 1.11	8	3	0.78	0.04	3.85
LRP1	rs1799986 (exon 3)	0.94	0.83, 1.06	27	5	1.42	0.01	3.52
MPO	rs2333227	1.01	0.80, 1.28	9	3	0.40	0.01	7.5
PLAU	rs2227564	1.07	0.94, 1.21	21	6	1.28	<0.001	4.69
SLC6A4	HTTLPR	1.04	0.83, 1.31	9	2	0.46	0.07	4.35
TFCP2	3′-UTR	0.77	0.55, 1.07	7	4	1.26	0.02	3.17

Abbreviations: ABCA1, ATP-binding cassette transporter A1; ACE, angiotensin-converting enzyme; APBB2, amyloid beta (A4) precursor protein-binding family B, member 2; APOE, apolipoprotein E; BCHE, butyrylcholinesterase; BDNF, brain-derived neurotrophic factor; CTSD, cathepsin D; ESR1, estrogen receptor 1; HTTLPR, serotonin-transporter-linked polymorphic region; IL6, interleukin-6; IL10, interleukin-10; LRP1, low density lipoprotein-related protein 1; MPO, myeloperoxidase; PLAU, plasminogen activator, urokinase; SLC6A4, serotonin transporter gene; TCFP2, transcription factor CP2; UTR, untranslated region.

^aP value for the difference between O and E (i.e., O − E).